Wockhardt's Novel Antibiotic Zaynich® Successfully Treats Pan-drug Resistant Infection in U.S. Liver Transplant Patient

A critically ill U.S. liver transplant patient suffering from a pan-drug resistant infection, resistant to all available antibiotics in the United States, was successfully treated with Wockhardt’s novel antibiotic Zaynich® (Zidebactam/Cefepime, WCK 5222). The patient was infected with two different pathogens, both resistant to recently introduced antibiotics. After 10 weeks of treatment with other antibiotics, the patient was administered Zaynich® for 14 days around the time of the liver transplant. The patient improved clinically within 11 days, showed no signs of active infection after six weeks, and the liver transplant was successful.